Artificial intelligence is stepping into one of healthcare’s most challenging frontiers: addressing the growing loneliness epidemic among elderly Americans. While this might sound like science fiction, AI-powered companionship represents a rapidly expanding market that could reach $44 billion this year, according to Research and Markets data.
The timing couldn’t be more critical. Approximately one-third of U.S. adults between ages 50 and 80 report feeling isolated, according to research published in the Journal of the American Medical Association. This loneliness carries serious health consequences, from depression to heart disease, creating medical challenges that traditional healthcare systems struggle to address effectively.
Several startups are now building businesses around AI-powered conversation partners specifically designed for older adults. Meela, which recently secured $3.5 million in seed funding, offers “friend-like” AI conversations for $40 monthly. The service has found early adoption among retirement communities, including RiverSpring Living in the Bronx, where elderly residents engage with AI companions designed to provide consistent, patient interaction.
Another company, InTouch, takes a different approach by using artificial intelligence to draw from a database of 1,400 conversation prompts. These prompts encourage seniors to share stories about their early lives and discuss favorite hobbies, creating structured yet natural dialogue that can help combat isolation.
“The first humans that actually live with an AI and are building a long-term relationship are not like geeks in Silicon Valley,” explains Dor Skuler, founder and CEO of Intuition Robotics, another player in this emerging space. “It is older adults in the United States.”
This trend reflects a broader shift in how AI applications are finding real-world adoption outside traditional tech circles, with elderly users becoming unexpected pioneers in human-AI relationships.
Meanwhile, in cancer treatment, a deceptively simple design change is revolutionizing how hospitals approach proton therapy, one of the most advanced forms of radiation treatment available. For decades, Stanford Health Care had attempted to install a proton therapy machine but couldn’t find adequate space for the massive equipment typically required.
Traditional proton therapy systems are enormous contraptions that need facilities roughly the size of a three-story football field, with construction costs ranging from $50 million to $100 million. Even prestigious institutions like Stanford found these requirements prohibitive, particularly given Palo Alto’s expensive real estate market.
Three years ago, Stanford discovered an innovative alternative through Leo Cancer Care, a startup that reimagined the fundamental design of proton therapy delivery. Instead of rotating a radiation beam around patients lying flat, the company developed a system where seated patients rotate around a stationary beam using a specialized chair.
This seemingly simple modification produced dramatic results. The space requirement dropped from more than 29,000 square feet to approximately 1,700 square feet—a reduction of over 90 percent. This dramatic downsizing made proton therapy installations significantly more affordable and feasible for hospitals with space constraints.
Stanford partnered with Leo Cancer Care, which provides the rotating chair and imaging technology, along with Mevion Medical Systems, which developed the compact proton accelerator. Construction began in 2024, with Stanford’s radiation oncology team optimistic about improved treatment outcomes.
“The concept is very simple, but the implementation is quite sophisticated,” notes Dr. Billy Loo, a Stanford professor of radiation oncology involved in the project. “It has a huge impact.”
Leo Cancer Care, based in West Sussex, UK, and Middleton, Wisconsin, has raised $150 million at a $280 million valuation, including a recent $40 million funding round led by Catalio Capital Management. The company’s flagship product, called Marie after Nobel laureate Marie Curie, combines the upright patient positioning system with a CT scanner and received FDA clearance in July.
Revenue reached $11 million last year and is expected to more than double this year. CEO Stephen Towe projects reaching $200 million in revenue within three to four years and indicates the company is “actively pursuing an IPO,” potentially as early as late 2026.
Recent presentations at the European Society for Medical Oncology Congress in Berlin revealed several significant advances in cancer treatment, particularly in areas that have historically proven difficult to treat effectively.
Moderna, the company that became famous for its COVID-19 vaccine, presented early clinical trial data for an mRNA-based cancer vaccine used in combination with Merck’s established cancer drug Keytruda in melanoma patients. The mRNA vaccine works by training the patient’s immune system to recognize and attack both tumor cells and tumor suppressor cells—a dual approach that achieved a 60 percent disease control rate in the study.
This represents a significant evolution of mRNA technology beyond infectious disease prevention into active cancer treatment. The approach leverages the same messenger RNA principles used in COVID vaccines but reprograms them to target cancer-specific proteins rather than viral ones.
Additionally, researchers at MD Anderson Cancer Center found an unexpected connection between COVID vaccination and cancer treatment success. Patients who received an mRNA COVID vaccine within 100 days of beginning cancer immunotherapy were twice as likely to survive three years compared to patients who did not receive the COVID vaccine, suggesting potential synergistic effects between the two treatments.
Ovarian cancer, often called a “silent killer” due to its tendency to remain undetected until advanced stages, saw multiple promising developments. Faeth Therapeutics, a clinical-stage startup, reported that its phase II study of sapanisertib combined with chemotherapy helped ovarian cancer patients survive longer, with a 34 percent reduction in progression risk compared to chemotherapy alone. The company plans to advance to phase III trials based on these results.
Merck presented data on raludotatug deruxtecan, an investigational antibody-drug conjugate developed in partnership with Daiichi Sankyo, a Japanese pharmaceutical company. Antibody-drug conjugates work like guided missiles, using antibodies to deliver toxic drugs directly to cancer cells while sparing healthy tissue. In the phase II/III study, tumors shrank in just over 50 percent of patients with ovarian, peritoneal, or fallopian tube cancers.
These developments are particularly significant for Merck as the company faces the looming loss of patent protection for Keytruda, which generated nearly $30 billion in revenue last year. The success of these new treatments could help offset that impending revenue decline.
AstraZeneca, the British-Swedish pharmaceutical giant, presented strong results for Enhertu, its breast cancer drug, across two separate clinical trials. In the first trial focusing on early-stage disease, 67 percent of patients achieved a complete pathological response—meaning no cancer cells were detectable after treatment—compared to 56 percent with standard treatment.
Complete pathological response is considered the gold standard in cancer treatment evaluation because it typically correlates with long-term survival and reduced recurrence risk. The second trial found that 92 percent of early HER2-positive breast cancer patients receiving Enhertu survived cancer-free after three years, compared to 84 percent receiving standard treatment.
Grail, a diagnostics company focused on early cancer detection, reported significant improvements in cancer screening effectiveness. The company’s Galleri test, designed to detect multiple cancer types simultaneously through blood analysis, proved three times more effective at finding breast, cervical, colorectal, and lung cancers when used alongside standard screening methods rather than those screenings alone.
This multi-cancer detection approach represents a shift from single-disease screening toward comprehensive cancer surveillance, potentially catching cancers that might otherwise go undetected until later stages when treatment becomes more challenging and expensive.
Beyond treatment innovations, a new startup is applying ride-sharing technology principles to solve healthcare’s notorious navigation challenges. Sage Care emerged from stealth mode with $20 million in funding, founded by veterans from rideOS and Carbon Health who recognized that healthcare systems suffer from coordination problems similar to those that ride-sharing platforms solved for transportation.
The company’s software creates what founders describe as an “air-traffic control system for healthcare,” designed to streamline patient flow through complex medical systems. This includes coordinating appointment scheduling, managing referrals between specialists, and ensuring patients receive appropriate care at optimal times—challenges that often frustrate both patients and healthcare providers.
Early customers include Jiva Health, a multi-specialty medical clinic in California; Bronson Healthcare, a large health system in Michigan; and White Plains Hospital in New York. The approach reflects growing recognition that healthcare delivery problems often stem from operational inefficiencies rather than clinical limitations.
These developments collectively illustrate how technology is addressing healthcare challenges across multiple dimensions simultaneously. AI companions tackle the social determinants of health among elderly populations, while engineering innovations make advanced cancer treatments more accessible by reducing facility requirements.
Meanwhile, biotechnology advances are expanding treatment options for historically difficult cancers, and operational technology is streamlining healthcare delivery itself. This convergence suggests that healthcare innovation is moving beyond single-point solutions toward comprehensive ecosystem improvements.
The success of these varied approaches indicates that healthcare’s most persistent challenges may require diverse technological interventions rather than singular breakthrough treatments. As these technologies mature and prove their effectiveness, they could fundamentally reshape how healthcare is delivered and experienced across different patient populations and medical conditions.
Join hosts Anthony, Shane, and Francesca for essential insights on AI's impact on jobs, careers, and business. Stay ahead of the curve – listen now!
Join hosts Anthony, Shane, and Francesca for essential insights on AI's impact on jobs, careers, and business. Stay ahead of the curve – listen now!
No hype. No doom. Just actionable resources and strategies to accelerate your success in the age of AI.
